It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Glaxo, Vir stop Covid trial early after drug shows 85% efficacy

Thu 11 March 2021 08:17 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Drug companies GlaxoSmithKline and Vir Biotechnology have been advised to finish a final trial of their Covid-19 drug early due to its "profound efficacy".

The duo said they would now seek authorisation in the US and other countries after phase-three clinical trials for the VIR-7831 treatment showed the drug reduced hospitalisation and risk of death by 85% and was effective against other variants. Shares in Vir rocketed 60% to $75 in pre-market trade on the news.

As a result, an independent data monitoring committee, recommended an early end to the trials.

An additional study also indicated the treatment maintained activity against "current circulating variants of concern" including the UK, South Africa and Brazilian strains.

Vir chief executive George Scangos said the results "bring us one step closer to delivering an effective new solution to patients around the globe".

"The dual-action design of VIR-7831 to both block viral entry into healthy cells and clear infected cells, as well as its high barrier to resistance, are key distinguishing characteristics."

"These findings, paired with our pending publication of resistance data, demonstrate the potential of VIR-7831 to prevent the most severe consequences of Covid-19 and highlight its potential ability to protect against the current circulating strains of the virus."

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast